ImpediMed Limited

ASX:IPD Stock Report

Mkt Cap: AU$335.2m

We’ve recently updated our valuation analysis.

ImpediMed Valuation

Is IPD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPD?

Other financial metrics that can be useful for relative valuation.

IPD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue28.1x
Enterprise Value/EBITDA-13.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does IPD's PS Ratio compare to its peers?

The above table shows the PS ratio for IPD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average13.4x
CYC Cyclopharm
7.2x21.1%AU$178.2m
EMV EMVision Medical Devices
17.5x-8.7%AU$102.8m
SOM SomnoMed
0.9x13.5%AU$74.5m
OIL Optiscan Imaging
28xn/aAU$53.2m
IPD ImpediMed
30.4x48.3%AU$335.2m

Price-To-Sales vs Peers: IPD is expensive based on its Price-To-Sales Ratio (30.4x) compared to the peer average (13.4x).

Price to Earnings Ratio vs Industry

How does IPD's PE Ratio compare vs other companies in the AU Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.3%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.3%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: IPD is expensive based on its Price-To-Sales Ratio (30.4x) compared to the Australian Medical Equipment industry average (4.8x)

Price to Sales Ratio vs Fair Ratio

What is IPD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio30.4x
Fair PS Ratio29.6x

Price-To-Sales vs Fair Ratio: IPD is expensive based on its Price-To-Sales Ratio (30.4x) compared to the estimated Fair Price-To-Sales Ratio (29.6x).

Share Price vs Fair Value

What is the Fair Price of IPD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IPD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IPD's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IPD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.16
AU$0.17
+3.2%
37.0%AU$0.21AU$0.06n/a4
May ’24AU$0.17
AU$0.16
-1.5%
38.3%AU$0.23AU$0.06n/a4
Apr ’24AU$0.10
AU$0.18
+74.6%
19.6%AU$0.23AU$0.14n/a3
Mar ’24AU$0.061
AU$0.15
+141.3%
47.1%AU$0.23AU$0.04n/a4
Feb ’24AU$0.061
AU$0.17
+170.6%
56.4%AU$0.30AU$0.04n/a4
Jan ’24AU$0.079
AU$0.18
+126.3%
51.7%AU$0.30AU$0.04n/a4
Dec ’23AU$0.092
AU$0.18
+94.3%
51.7%AU$0.30AU$0.04n/a4
Nov ’23AU$0.092
AU$0.18
+94.3%
51.7%AU$0.30AU$0.04n/a4
Oct ’23AU$0.063
AU$0.18
+183.8%
51.7%AU$0.30AU$0.04n/a4
Sep ’23AU$0.064
AU$0.18
+179.3%
51.7%AU$0.30AU$0.04n/a4
Aug ’23AU$0.069
AU$0.30
+338.1%
29.0%AU$0.41AU$0.19n/a3
Jul ’23AU$0.06
AU$0.32
+432.1%
21.3%AU$0.41AU$0.25n/a3
Jun ’23AU$0.086
AU$0.32
+271.2%
21.3%AU$0.41AU$0.25AU$0.143
May ’23AU$0.12
AU$0.32
+166.1%
21.3%AU$0.41AU$0.25AU$0.173
Apr ’23AU$0.14
AU$0.31
+112.1%
20.2%AU$0.41AU$0.25AU$0.104
Mar ’23AU$0.17
AU$0.31
+86.4%
20.2%AU$0.41AU$0.25AU$0.0614
Feb ’23AU$0.19
AU$0.31
+62.7%
20.1%AU$0.41AU$0.25AU$0.0614
Jan ’23AU$0.17
AU$0.32
+84.0%
20.8%AU$0.41AU$0.25AU$0.0793
Dec ’22AU$0.17
AU$0.32
+89.4%
20.8%AU$0.41AU$0.25AU$0.0923
Nov ’22AU$0.19
AU$0.26
+37.9%
12.9%AU$0.31AU$0.23AU$0.0923
Oct ’22AU$0.12
AU$0.22
+82.2%
4.6%AU$0.23AU$0.21AU$0.0633
Sep ’22AU$0.13
AU$0.22
+74.9%
4.6%AU$0.23AU$0.21AU$0.0643
Aug ’22AU$0.095
AU$0.22
+131.6%
3.7%AU$0.23AU$0.21AU$0.0693
Jul ’22AU$0.11
AU$0.22
+98.8%
4.5%AU$0.23AU$0.21AU$0.063
Jun ’22AU$0.13
AU$0.22
+74.9%
4.5%AU$0.23AU$0.21AU$0.0863

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies